

# VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.  
Phone: 07405699869, email: info@vivanzabiosciences.com, web: www.vivanzabiosciences.com  
CIN: L24110GJ1982PLC005057

Date: July, 24, 2021

To,  
BSE Limited  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001

Ref.: BSE Scrip Code No. "530057"

Respected Sir/Madam,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Saturday, July 24, 2021 (which commenced at 04.00 p.m. and concluded at 04.35 p.m., inter alia, has approved/ noted the following:-

**1. Approval of the Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2021:**

Upon recommendation of the Audit Committee, the Board of Directors has approved the Unaudited Standalone and Consolidated Financial Results as per Indian Accounting Standards (IND AS) for the Quarter ended June 30, 2021 (enclosed herewith).

**2. Noting of the Limited Review Report of the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2021:**



The Limited Review Report of the Statutory Auditors for the Quarter ended June 30, 2021. The Board of Directors took note of the same (enclosed herewith).

We request you to please take the above information on your records.

Thanking you,

Yours sincerely,

For Vivanza Biosciences Limited



Jainil Bhatt  
Chief Financial Officer  
PAN: AJDPB2629L

Encl: As above



Limited review report on the Un-audited Consolidated Financial Results for the quarter ended 30 June, 2021, pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,  
The Board of Directors,  
M/s Vivanza Biosciences Limited

We have reviewed the accompanying statement of Unaudited Consolidated Financial results of M/s Vivanza Biosciences Limited ("the Company") and its subsidiary ( the Parent and its Subsidiary together referred to as "the Group"), for the quarter ended 30<sup>th</sup> June,2021, ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 , as amended.

This statement is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India read with the Circular. Our responsibility is to issue a report on the consolidated financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statements includes the results of following entity ("the Subsidiary"): Vivanza Lifesciences Private Limited.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards as notified under the Companies (India Accounting Standards) Rules,2015 as specified in Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the financial results of subsidiary included in the consolidated unaudited financial results. These interim financial statement of the subsidiary have been reviewed by other auditor





# GMCA & Co.

Chartered Accountants

whose report has been furnished to us by the management and our conclusion on the statement, so far as it relates to amounts and disclosures included in respect of this subsidiary is based solely on the report of the auditor of the company and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the matter.



Place: Ahmedabad  
Date: 24<sup>th</sup> July, 2021

For, G M C A & CO.  
Chartered Accountants  
FRN: 109850W

*San*  
CA. Mitt S. Patel  
Partner  
Membership No: 163940  
UDIN: 21163940AAAAQG4906

## VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

Ph.No.:079-26670952/54 Email Id: info@vivanzabiosciences.com Website : www.vivanzabiosciences.com

### STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended
	30/06/2021	31/03/2021	30/6/2020	31/03/2021
	Unaudited	Audited	Unaudited	Audited
<b>1 Income from Operations</b>				
(a) Revenue from operations	22.63	290.57	68.68	988.83
(b) Other Income	48.33	10.33	0.34	50.58
<b>Total Income</b>	<b>70.96</b>	<b>300.90</b>	<b>69.02</b>	<b>1039.39</b>
<b>2 Expenses</b>				
(a) Cost of Materials consumed	0.00	0.00	0	0.00
(b) Purchase of stock-in-trade	11.23	262.78	116.64	883.92
(c) Increase/Decrease in Inventories of FG, WIP and stock-in-trade	0.6	14.62	-50.82	31.38
(d) Employee benefits expense	6.07	5.31	11.08	33.91
(e) Finance Cost	11.55	10.39	0.69	48.76
(f) Depreciation and amortisation expense	0.18	0.35	0	0.98
(g) Other expenses	9.15	15.47	8.31	30.09
<b>Total Expenses</b>	<b>38.78</b>	<b>308.92</b>	<b>86.90</b>	<b>1027.06</b>
<b>3 Profit/(loss) before exceptional items and tax (1-2)</b>	<b>32.18</b>	<b>-8.01</b>	<b>-16.88</b>	<b>12.34</b>
4 Exceptional Items	0.00	0.00	0.00	0.00
<b>5 Profit/(Loss) before tax (3-4)</b>	<b>32.18</b>	<b>-8.01</b>	<b>-16.88</b>	<b>12.34</b>
<b>6 Tax Expense</b>				
(a) Current tax	0.00	4.85	0.00	4.85
(b) Deferred tax	0.00	-0.04	0.00	-0.04
<b>Total Tax Expenses</b>	<b>0.00</b>	<b>4.81</b>	<b>0.00</b>	<b>4.81</b>
<b>7 Profit / (Loss) for the period from continuing operations (5-6)</b>	<b>32.18</b>	<b>-12.83</b>	<b>-16.88</b>	<b>7.53</b>
8 Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00
<b>10 Profit (Loss) from discontinuing operations (after tax)(8-9)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>11 Other Comprehensive Income</b>				
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
<b>B (i) Items that will be reclassified to profit or loss</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
<b>Other Comprehensive Income for the period</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12 Total Comprehensive income for the period</b>	<b>32.18</b>	<b>-12.83</b>	<b>-16.88</b>	<b>7.53</b>
13 Paid-up equity share capital (Face value of Rs.10/- each)	400	400	400	400
14 Other Equity	-	-	-	(84.06)
<b>15 Earnings Per Share (before extraordinary items) (not annualised):</b>				
(a) Basic	0.80	-0.32	-0.42	0.19
(b) Diluted	0.80	-0.32	-0.42	0.19
<b>16 Earnings Per Share (after extraordinary items) (not annualised):</b>				
(a) Basic	0.80	-0.32	-0.42	0.19
(b) Diluted	0.80	-0.32	-0.42	0.19

**Notes:**

1. The above audited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on July 24, 2021. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended June 30, 2021.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e. pharmaceuticals related activities

For, VIVANZA BIOSCIENCES LIMITED

JAINIL RASESHKUMAR BHATT  
CFO

PAN : AJDPB2634L \*

Date : 24/07/2021

Place : Ahmedabad





# GMCA & Co.

Chartered Accountants

Limited review report on the Un-audited Standalone Financial Results for the quarter ended 30<sup>th</sup> June, 2021, pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,  
The Board of Directors,  
**Vivanza Biosciences Limited**  
Ahmedabad

We have reviewed the accompanying statement of Un-audited Standalone Financial Results of **Vivanza Biosciences Limited** ("the Company") for the quarter ended 30<sup>th</sup> June, 2021, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India read with the Circular. Our responsibility is to issue a report on the financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards as notified under the Companies (India Accounting Standards) Rules, 2015 as specified in Section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Ahmedabad  
Date: 24<sup>th</sup> July, 2021

For, GMCA & CO.  
Chartered Accountants  
FRN: 109850W

  
CA. Mitt S. Patel  
Partner  
Membership No: 163940  
UDIN: 21163940AAAAQF3148

## VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

Ph.No.:079-26870952/54 Email Id: info@vivanzabiosciences.com Website : www.vivanzabiosciences.com

**STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021**

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended
	30/06/2021	31/03/2021	30/6/2020	31/03/2021
	Unaudited	Audited	Unaudited	Audited
<b>1 Income from Operations</b>				
(a) Revenue from operations	19.76	279.59	44.07	922.34
(b) Other Income	48.33	7.87	0.12	49.98
<b>Total Income</b>	<b>68.09</b>	<b>287.46</b>	<b>44.19</b>	<b>972.32</b>
<b>2 Expenses</b>				
(a) Cost of Materials consumed	0.00	0.00	0	0.00
(b) Purchase of stock-in-trade	11.22	258.67	92.27	810.62
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-1.38	12.33	-50.82	45.66
(d) Employee benefits expense	1.65	4.55	9.85	29.08
(e) Finance Cost	11.55	10.65	0.69	46.76
(f) Depreciation and amortisation expense	0.18	0.35	0	0.98
(g) Other expenses	8.19	11.26	8.22	24.42
<b>Total Expenses</b>	<b>31.41</b>	<b>297.81</b>	<b>60.21</b>	<b>967.63</b>
<b>3 Profit/(loss) before exceptional items and tax (1-2)</b>	<b>36.68</b>	<b>-10.35</b>	<b>-16.02</b>	<b>14.79</b>
<b>4 Exceptional Items</b>	0.00	0.00	0.00	0.00
<b>5 Profit/(Loss) before tax (3-4)</b>	<b>36.68</b>	<b>-10.35</b>	<b>-16.02</b>	<b>14.79</b>
<b>6 Tax Expense</b>				
(a) Current tax	0.00	4.85	0.00	4.85
(b) Deferred tax	0.00	-0.04	0.00	-0.04
<b>Total Tax Expenses</b>	<b>0.00</b>	<b>4.81</b>	<b>0.00</b>	<b>4.81</b>
<b>7 Profit / (Loss) for the period from continuing operations (5-6)</b>	<b>36.68</b>	<b>-15.16</b>	<b>-16.02</b>	<b>9.98</b>
<b>8 Profit (Loss) from discontinuing operations</b>	0.00	0.00	0.00	0.00
<b>9 Tax Expense of discontinuing operations</b>	0.00	0.00	0.00	0.00
<b>10 Profit (Loss) from discontinuing operations (after tax)(8-9)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>11 Other Comprehensive Income</b>		0.00		0.00
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
<b>B (i) Items that will be reclassified to profit or loss</b>	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	-15.16	0.00	9.98
<b>Other Comprehensive Income for the period</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12 Total Comprehensive Income for the period</b>	<b>36.68</b>	<b>-15.16</b>	<b>-16.02</b>	<b>9.98</b>
<b>13 Paid-up equity share capital (Face value of Rs.10/- each)</b>	400	400	400	400
<b>14 Other Equity</b>	-	-	-	-63.49
<b>15 Earnings Per Share (before extraordinary items) (not annualised):</b>				
(a) Basic	0.91	-0.38	-0.40	0.25
(b) Diluted	0.91	-0.38	-0.40	0.25
<b>16 Earnings Per Share (after extraordinary items) (not annualised):</b>				
(a) Basic	0.91	-0.38	-0.40	0.25
(b) Diluted	0.91	-0.38	-0.40	0.25

**Notes:**

- The above audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on July 24, 2021. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended June 30, 2021.
- The Company adopted the Indian Accounting Standards ("Ind AS") effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.
- The Company operates only in single segment i.e. pharmaceuticals related activities.

For, VIVANZA BIOSCIENCES LIMITED

JAINIL RASESHKUMAR BHATT  
CFO

PAN : AJDPB2629L

Date : 24/07/2021

Place : Ahmedabad

